强生-话题@MedSci

#强生#

169篇内容 | 4616人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1271665, encodeId=c2b512e16659a, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, objectTitle=银屑病患者福音：FDA批准强生公司新药tremfya, objectType=article, longId=105620, objectId=b1e3105620cc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b1e3105620cc, replyNumber=0, likeNumber=56, createdTime=2017-07-17, rootId=0, userName=liuyong2980, userId=de89102, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b1e3105620cc, moduleTitle=银屑病患者福音：FDA批准强生公司新药tremfya, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b1e3105620cc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271664, encodeId=586412e166477, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, objectTitle=强生集团旗下杨森制药召开业务回顾大会展现强劲创新医药产品线, objectType=article, longId=99454, objectId=512199454c1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=512199454c1, replyNumber=0, likeNumber=67, createdTime=2017-05-25, rootId=0, userName=liuyong2980, userId=de89102, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=512199454c1, moduleTitle=强生集团旗下杨森制药召开业务回顾大会展现强劲创新医药产品线, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=512199454c1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271663, encodeId=115312e1663fe, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, objectTitle=研发日报丨拜耳&强生宣布Xarelto预防VTE复发效果显著优于阿司匹林, objectType=article, longId=92817, objectId=c5769281ec6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c5769281ec6, replyNumber=0, likeNumber=59, createdTime=2017-03-23, rootId=0, userName=liuyong2980, userId=de89102, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c5769281ec6, moduleTitle=研发日报丨拜耳&强生宣布Xarelto预防VTE复发效果显著优于阿司匹林, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c5769281ec6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271662, encodeId=462712e166235, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, objectTitle=跨国药企发布2016成绩单，强生稳坐**！, objectType=article, longId=89204, objectId=fd05892045d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fd05892045d, replyNumber=0, likeNumber=68, createdTime=2017-02-18, rootId=0, userName=liuyong2980, userId=de89102, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fd05892045d, moduleTitle=跨国药企发布2016成绩单，强生稳坐**！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fd05892045d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271661, encodeId=d75612e16613a, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, objectTitle=强生300亿美元收购欧洲很大生物制药公司Actelion 开辟罕见病治疗领域, objectType=article, longId=88958, objectId=d61188958bc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d61188958bc, replyNumber=0, likeNumber=55, createdTime=2017-02-17, rootId=0, userName=liuyong2980, userId=de89102, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d61188958bc, moduleTitle=强生300亿美元收购欧洲很大生物制药公司Actelion 开辟罕见病治疗领域, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d61188958bc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271660, encodeId=b29812e1660e3, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, objectTitle=谷歌、强生、雅培将如何下注？成就医疗行业“登月计划”, objectType=article, longId=88884, objectId=8369888840d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8369888840d, replyNumber=0, likeNumber=68, createdTime=2017-02-16, rootId=0, userName=liuyong2980, userId=de89102, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8369888840d, moduleTitle=谷歌、强生、雅培将如何下注？成就医疗行业“登月计划”, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8369888840d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271659, encodeId=0eef12e165989, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, objectTitle=大动作！强生新年开展了哪15项新合作？, objectType=article, longId=87083, objectId=c9708e083ed, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c9708e083ed, replyNumber=0, likeNumber=60, createdTime=2017-01-11, rootId=0, userName=liuyong2980, userId=de89102, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c9708e083ed, moduleTitle=大动作！强生新年开展了哪15项新合作？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c9708e083ed)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271658, encodeId=368e12e1658be, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, objectTitle=强强联手！百时美与强生合作开发免疫组合疗法Opdivo+Darzalex，治疗多种肿瘤, objectType=article, longId=86946, objectId=6e9a869465e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6e9a869465e, replyNumber=0, likeNumber=58, createdTime=2017-01-09, rootId=0, userName=liuyong2980, userId=de89102, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6e9a869465e, moduleTitle=强强联手！百时美与强生合作开发免疫组合疗法Opdivo+Darzalex，治疗多种肿瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6e9a869465e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271657, encodeId=8eee12e16575c, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, objectTitle=强生向美国FDA提交重磅抗炎药Stelara补充生物制品许可（sBLA），治疗青少年斑块型银屑病, objectType=article, longId=85676, objectId=152b856e6bf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=152b856e6bf, replyNumber=0, likeNumber=50, createdTime=2016-12-29, rootId=0, userName=liuyong2980, userId=de89102, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=152b856e6bf, moduleTitle=强生向美国FDA提交重磅抗炎药Stelara补充生物制品许可（sBLA），治疗青少年斑块型银屑病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=152b856e6bf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271656, encodeId=5f1c12e165613, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, objectTitle=自然界神奇“偷基因”生存策略：给物种带来顽强生命力, objectType=article, longId=82612, objectId=039d82612ec, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=039d82612ec, replyNumber=0, likeNumber=58, createdTime=2016-11-19, rootId=0, userName=liuyong2980, userId=de89102, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=039d82612ec, moduleTitle=自然界神奇“偷基因”生存策略：给物种带来顽强生命力, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=039d82612ec)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271655, encodeId=2d1c12e1655c4, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, objectTitle=卫计委：关于加强生育全程基本医疗保健服务的若干意见, objectType=article, longId=81277, objectId=beda812e7b5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=beda812e7b5, replyNumber=0, likeNumber=61, createdTime=2016-10-30, rootId=0, userName=liuyong2980, userId=de89102, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=beda812e7b5, moduleTitle=卫计委：关于加强生育全程基本医疗保健服务的若干意见, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=beda812e7b5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271654, encodeId=ed4212e1654a9, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, objectTitle=类风湿新药进展！强生向美国FDA提交IL-6单抗sirukumab上市申请, objectType=article, longId=78354, objectId=5f55e835481, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5f55e835481, replyNumber=0, likeNumber=78, createdTime=2016-09-26, rootId=0, userName=liuyong2980, userId=de89102, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5f55e835481, moduleTitle=类风湿新药进展！强生向美国FDA提交IL-6单抗sirukumab上市申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5f55e835481)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271653, encodeId=c54512e1653f1, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, objectTitle=糖尿病重大喜讯！美国FDA批准强生复方新药Invokamet XR用于2型糖尿病一线治疗, objectType=article, longId=78309, objectId=48a1e83099a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=48a1e83099a, replyNumber=0, likeNumber=73, createdTime=2016-09-25, rootId=0, userName=liuyong2980, userId=de89102, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=48a1e83099a, moduleTitle=糖尿病重大喜讯！美国FDA批准强生复方新药Invokamet XR用于2型糖尿病一线治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=48a1e83099a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271652, encodeId=b9d812e16521c, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, objectTitle=强生危险！辉瑞英夫利昔生物类似药PF-06438179 III期临床获得成功, objectType=article, longId=77934, objectId=92cfe7934e2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=92cfe7934e2, replyNumber=0, likeNumber=76, createdTime=2016-09-21, rootId=0, userName=liuyong2980, userId=de89102, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=92cfe7934e2, moduleTitle=强生危险！辉瑞英夫利昔生物类似药PF-06438179 III期临床获得成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=92cfe7934e2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271651, encodeId=470f12e165167, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, objectTitle=中国强生发布《2015年在华企业公民与可持续发展报告》, objectType=article, longId=76432, objectId=d360e6432f9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d360e6432f9, replyNumber=0, likeNumber=106, createdTime=2016-09-03, rootId=0, userName=liuyong2980, userId=de89102, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d360e6432f9, moduleTitle=中国强生发布《2015年在华企业公民与可持续发展报告》, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d360e6432f9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271650, encodeId=71df12e1650d6, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, objectTitle=强生为Darzalex申请新适应症，进军多发性骨髓瘤二线治疗, objectType=article, longId=75557, objectId=f64ae5557dd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f64ae5557dd, replyNumber=0, likeNumber=48, createdTime=2016-08-22, rootId=0, userName=liuyong2980, userId=de89102, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f64ae5557dd, moduleTitle=强生为Darzalex申请新适应症，进军多发性骨髓瘤二线治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f64ae5557dd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271649, encodeId=b8bd12e1649f0, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, objectTitle=喜讯！强生潜在重磅抗抑郁药艾氯胺酮（esketamine）斩获FDA第2个突破性药物资格, objectType=article, longId=75385, objectId=bf21e538504, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bf21e538504, replyNumber=0, likeNumber=66, createdTime=2016-08-19, rootId=0, userName=liuyong2980, userId=de89102, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bf21e538504, moduleTitle=喜讯！强生潜在重磅抗抑郁药艾氯胺酮（esketamine）斩获FDA第2个突破性药物资格, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bf21e538504)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271648, encodeId=1b9a12e164871, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, objectTitle=强生、诺华二季度报一起看：重磅药物贡献大！, objectType=article, longId=74004, objectId=6e71e4004b6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6e71e4004b6, replyNumber=0, likeNumber=76, createdTime=2016-07-30, rootId=0, userName=liuyong2980, userId=de89102, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6e71e4004b6, moduleTitle=强生、诺华二季度报一起看：重磅药物贡献大！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6e71e4004b6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271647, encodeId=84b812e164726, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, objectTitle=GSK牵手强生共同开发哮喘药物---IL-33单抗, objectType=article, longId=73995, objectId=3062e39950a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3062e39950a, replyNumber=0, likeNumber=71, createdTime=2016-07-30, rootId=0, userName=liuyong2980, userId=de89102, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3062e39950a, moduleTitle=GSK牵手强生共同开发哮喘药物---IL-33单抗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3062e39950a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271646, encodeId=9d1512e164614, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, objectTitle=强生/Genmab联手拿下Darzalex突破性疗法地位进军二线用药市场, objectType=article, longId=73919, objectId=9afae391959, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9afae391959, replyNumber=0, likeNumber=88, createdTime=2016-07-29, rootId=0, userName=liuyong2980, userId=de89102, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9afae391959, moduleTitle=强生/Genmab联手拿下Darzalex突破性疗法地位进军二线用药市场, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9afae391959)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

强生

2020-05-29

liuyong2980 (审核中...)

前往app查看评论内容

#强生#

银屑病患者福音：FDA批准强生公司新药tremfya

2017-07-17

liuyong2980 (审核中...)

前往app查看评论内容

#强生#

强生集团旗下杨森制药召开业务回顾大会展现强劲创新医药产品线

2017-05-25

liuyong2980 (审核中...)

前往app查看评论内容

#强生#

研发日报丨拜耳&强生宣布Xarelto预防VTE复发效果显著优于阿司匹林

2017-03-23

liuyong2980 (审核中...)

前往app查看评论内容

#强生#

跨国药企发布2016成绩单，强生稳坐**！

2017-02-18

liuyong2980 (审核中...)

前往app查看评论内容

#强生#

强生300亿美元收购欧洲很大生物制药公司Actelion 开辟罕见病治疗领域

2017-02-17

liuyong2980 (审核中...)

前往app查看评论内容

#强生#

谷歌、强生、雅培将如何下注？成就医疗行业“登月计划”

2017-02-16

liuyong2980 (审核中...)

前往app查看评论内容

#强生#

大动作！强生新年开展了哪15项新合作？

2017-01-11

liuyong2980 (审核中...)

前往app查看评论内容

#强生#

强强联手！百时美与强生合作开发免疫组合疗法Opdivo+Darzalex，治疗多种肿瘤

2017-01-09

liuyong2980 (审核中...)

前往app查看评论内容

#强生#

强生向美国FDA提交重磅抗炎药Stelara补充生物制品许可（sBLA），治疗青少年斑块型银屑病

2016-12-29

liuyong2980 (审核中...)

前往app查看评论内容

#强生#

自然界神奇“偷基因”生存策略：给物种带来顽强生命力

2016-11-19

liuyong2980 (审核中...)

前往app查看评论内容

#强生#

卫计委：关于加强生育全程基本医疗保健服务的若干意见

2016-10-30

liuyong2980 (审核中...)

前往app查看评论内容

#强生#

类风湿新药进展！强生向美国FDA提交IL-6单抗sirukumab上市申请

2016-09-26

liuyong2980 (审核中...)

前往app查看评论内容

#强生#

糖尿病重大喜讯！美国FDA批准强生复方新药Invokamet XR用于2型糖尿病一线治疗

2016-09-25

liuyong2980 (审核中...)

前往app查看评论内容

#强生#

强生危险！辉瑞英夫利昔生物类似药PF-06438179 III期临床获得成功

2016-09-21

liuyong2980 (审核中...)

前往app查看评论内容

#强生#

中国强生发布《2015年在华企业公民与可持续发展报告》

2016-09-03

liuyong2980 (审核中...)

前往app查看评论内容

#强生#

强生为Darzalex申请新适应症，进军多发性骨髓瘤二线治疗

2016-08-22

liuyong2980 (审核中...)

前往app查看评论内容

#强生#

喜讯！强生潜在重磅抗抑郁药艾氯胺酮（esketamine）斩获FDA第2个突破性药物资格

2016-08-19

liuyong2980 (审核中...)

前往app查看评论内容

#强生#

强生、诺华二季度报一起看：重磅药物贡献大！

2016-07-30

liuyong2980 (审核中...)

前往app查看评论内容

#强生#

GSK牵手强生共同开发哮喘药物---IL-33单抗

2016-07-30

liuyong2980 (审核中...)

前往app查看评论内容

#强生#

强生/Genmab联手拿下Darzalex突破性疗法地位进军二线用药市场

2016-07-29

科室
- - 订阅+
  - 更多科室
工具
服务